Literature DB >> 34994539

Roles of VGLUT2 and Dopamine/Glutamate Co-Transmission in Selective Vulnerability to Dopamine Neurodegeneration.

Silas A Buck1,2, M Quincy Erickson-Oberg1,2, Sai H Bhatte2, Chase D McKellar2, Vishan P Ramanathan2, Sophie A Rubin2, Zachary Freyberg2,3.   

Abstract

Growing evidence has established that a subset of dopamine (DA) neurons co-release glutamate and express vesicular glutamate transporter 2 (VGLUT2). VGLUT2 expression in DA neurons plays a key role in selective vulnerability to DA neurodegeneration in Parkinson's disease (PD). In this review, we summarize recent findings on impacts of VGLUT2 expression and glutamate co-release from DA neurons on selective DA neuron vulnerability. We present evidence that DA neuron VGLUT2 expression may be neuroprotective, boosting DA neuron resilience in the context of ongoing neurodegenerative processes in PD. We highlight genetic and pesticide models of PD that have provided mechanistic insights into selective DA neuron vulnerability. Finally, we discuss potential neuroprotective mechanisms, focusing on roles of VGLUT2 and glutamate in promoting mitochondrial health and diminishing oxidative stress and excitotoxicity. Elucidating these mechanisms may ultimately lead to more effective treatments to boost DA neuron resilience that can slow or even prevent DA neurodegeneration.

Entities:  

Keywords:  Dopamine; Parkinson’s disease; VGLUT2; co-release; glutamate; neurodegeneration

Mesh:

Substances:

Year:  2022        PMID: 34994539      PMCID: PMC9242677          DOI: 10.1021/acschemneuro.1c00741

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   5.780


  57 in total

Review 1.  Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease.

Authors:  A Plaitakis; P Shashidharan
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

2.  Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3.

Authors:  Phillip M Rappold; Mei Cui; Adrianne S Chesser; Jacqueline Tibbett; Jonathan C Grima; Lihua Duan; Namita Sen; Jonathan A Javitch; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 3.  Pathogenic mutations in Parkinson disease.

Authors:  Eng-King Tan; Lisa M Skipper
Journal:  Hum Mutat       Date:  2007-07       Impact factor: 4.878

4.  Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology.

Authors:  Robert E Drolet; Jason R Cannon; Laura Montero; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2009-07-10       Impact factor: 5.996

5.  Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics.

Authors:  I Irrcher; H Aleyasin; E L Seifert; S J Hewitt; S Chhabra; M Phillips; A K Lutz; M W C Rousseaux; L Bevilacqua; A Jahani-Asl; S Callaghan; J G MacLaurin; K F Winklhofer; P Rizzu; P Rippstein; R H Kim; C X Chen; E A Fon; R S Slack; M E Harper; H M McBride; T W Mak; D S Park
Journal:  Hum Mol Genet       Date:  2010-07-16       Impact factor: 6.150

6.  Dopamine neurons exhibit emergent glutamatergic identity in Parkinson's disease.

Authors:  Thomas Steinkellner; William S Conrad; Imre Kovacs; Robert A Rissman; Edward B Lee; John Q Trojanowski; Zachary Freyberg; Subhojit Roy; Kelvin C Luk; Virginia M Lee; Thomas S Hnasko
Journal:  Brain       Date:  2022-04-29       Impact factor: 15.255

7.  VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation.

Authors:  Carolina Birgner; Karin Nordenankar; Martin Lundblad; José Alfredo Mendez; Casey Smith; Madeleine le Grevès; Dagmar Galter; Lars Olson; Anders Fredriksson; Louis-Eric Trudeau; Klas Kullander; Asa Wallén-Mackenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

Review 8.  Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics.

Authors:  Juan Camilo Jurado-Coronel; Ricardo Cabezas; Marco Fidel Ávila Rodríguez; Valentina Echeverria; Luis Miguel García-Segura; George E Barreto
Journal:  Front Neuroendocrinol       Date:  2017-09-30       Impact factor: 8.606

9.  Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation.

Authors:  Sabrina Heinz; Alexius Freyberger; Bettina Lawrenz; Ludwig Schladt; Gabriele Schmuck; Heidrun Ellinger-Ziegelbauer
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

10.  Mapping projections of molecularly defined dopamine neuron subtypes using intersectional genetic approaches.

Authors:  Jean-Francois Poulin; Giuliana Caronia; Caitlyn Hofer; Qiaoling Cui; Brandon Helm; Charu Ramakrishnan; C Savio Chan; Daniel A Dombeck; Karl Deisseroth; Rajeshwar Awatramani
Journal:  Nat Neurosci       Date:  2018-08-13       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.